tislelizumab + platinum-based chemotherapy

**Tislelizumab + platinum-based chemotherapy** is a combination regimen used primarily as first-line treatment in various forms of advanced lung cancer and other solid tumors. **Tislelizumab** is a humanized monoclonal antibody targeting the programmed death receptor 1 (**PD-1**) on T cells, designed to block inhibitory signaling from its ligands PD-L1 and PD-L2, which are exploited by tumor cells to evade immune detection. By preventing this interaction, tislelizumab reactivates T-cell–mediated antitumor immunity. The regimen typically combines tislelizumab (administered as an intravenous infusion every 3 weeks) with a platinum-based chemotherapy doublet (such as cisplatin or carboplatin plus agents like pemetrexed, etoposide, paclitaxel, or gemcitabine) tailored to cancer histology. This combination has demonstrated improved progression-free survival and objective response rates compared to chemotherapy alone in extensive-stage small cell lung cancer (SCLC) and advanced non–small-cell lung cancer (NSCLC), and is approved/under regulatory recommendation as first-line therapy in these settings[1][3][7].

Brand names

TevimbraTislelizumab-jsgr

Other names

tislelizumab + platinum-based chemotherapy